You’re FDA approved, now what? How biopharmas successfully plan for and make the transition from the development stage to commercial companies.
Emerging life science companies dream of their first regulatory approval, but the skills and capabilities required for success can change dramatically overnight once that goal is reached. Moreover, startup culture may clash with the requirements of running a commercial business. Join us for a lively discussion of what emerging companies must do before, during and after achieving the holy grail of approval to ensure long term success.
Note: Food will be provided.
5:00 p.m. - 6:10 p.m. Registration, Networking and Reception
6:15 p.m. - 7:15 p.m. Panel Discussion
7:15 p.m. - 8:00 p.m. Networking
Philina Lee – VP Marketing, Patient Services, and Precision Medicine, Blueprint Medicines
Lauren Barnes – SVP, Market Access and Reimbursement, Blueprint Medicines
Tanya Green – Senior Director, Regulatory Affairs, Blueprint Medicines
Nerissa Kreher – Chief Medical Officer, Tiburio Therapeutics
Until February 21, 2020
- Non-Members/Free Unlimited Guest Members*: $55
Beginning February 22, 2020
- Non-Members/Free Unlimited Guest Members*: $60
*To access the Member rate, click here to purchase a WIB membership.
Special Guest Pricing
Members can register guests at member price.
* - Walk-ins will be accepted until event capacity is reached.
Metered parking and several garages in area. (Pilgrim Street and Landsdowne Street)
Directions from Public Transit
T Stop: red line, Central Square (0.03 mile walk)